Association of Sarcopenia and Its Defining Components with the Degree of Cognitive Impairment in a Memory Clinic Population.

Humans Female Aged Sarcopenia / complications Muscle Strength Cognitive Dysfunction / diagnosis Hand Strength / physiology Walking Speed
Alzheimer’s disease body composition cognitive function gait speed hand grip strength outpatients sarcopenia

Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2023
Historique:
medline: 14 11 2023
pubmed: 30 10 2023
entrez: 29 10 2023
Statut: ppublish

Résumé

Sarcopenia and cognitive impairment are two leading causes of disabilities. The objective was to examine the prevalence of sarcopenia and investigate the association between sarcopenia diagnostic components (muscle strength, muscle mass, and physical performance) and cognitive impairment in memory clinic patients. 368 patients were included (age 59.0±7.25 years, women: 58.7%), displaying three clinical phenotypes of cognitive impairments, i.e., subjective cognitive impairment (SCI, 57%), mild cognitive impairment (MCI, 26%), and Alzheimer's disease (AD, 17%). Sarcopenia was defined according to diagnostic algorithm recommended by the European Working Group on Sarcopenia in Older People. Components of sarcopenia were grip strength, bioelectrical impedance analysis, and gait speed. They were further aggregated into a score (0-3 points) by counting the numbers of limited components. Multi-nominal logistic regression was applied. Probable sarcopenia (i.e., reduced grip strength) was observed in 9.6% of the patients, and 3.5% were diagnosed with sarcopenia. Patients with faster gait speed showed less likelihood of MCI (odds ratio [OR]: 0.24, 95% confidence interval [CI]: 0.06-0.90) and AD (OR: 0.12, 95% CI: 0.03-0.60). One or more limited sarcopenia components was associated with worse cognitive function. After adjusting for potential confounders, the association remained significant only for AD (OR 4.29, 95% CI 1.45-11.92). The results indicate a connection between the sarcopenia components and cognitive impairments. Limitations in the sarcopenia measures, especially slow walking speed, were related to poorer cognitive outcomes. More investigationsare required to further verify the causal relationship between sarcopenia and cognitive outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Sarcopenia and cognitive impairment are two leading causes of disabilities.
OBJECTIVE OBJECTIVE
The objective was to examine the prevalence of sarcopenia and investigate the association between sarcopenia diagnostic components (muscle strength, muscle mass, and physical performance) and cognitive impairment in memory clinic patients.
METHODS METHODS
368 patients were included (age 59.0±7.25 years, women: 58.7%), displaying three clinical phenotypes of cognitive impairments, i.e., subjective cognitive impairment (SCI, 57%), mild cognitive impairment (MCI, 26%), and Alzheimer's disease (AD, 17%). Sarcopenia was defined according to diagnostic algorithm recommended by the European Working Group on Sarcopenia in Older People. Components of sarcopenia were grip strength, bioelectrical impedance analysis, and gait speed. They were further aggregated into a score (0-3 points) by counting the numbers of limited components. Multi-nominal logistic regression was applied.
RESULTS RESULTS
Probable sarcopenia (i.e., reduced grip strength) was observed in 9.6% of the patients, and 3.5% were diagnosed with sarcopenia. Patients with faster gait speed showed less likelihood of MCI (odds ratio [OR]: 0.24, 95% confidence interval [CI]: 0.06-0.90) and AD (OR: 0.12, 95% CI: 0.03-0.60). One or more limited sarcopenia components was associated with worse cognitive function. After adjusting for potential confounders, the association remained significant only for AD (OR 4.29, 95% CI 1.45-11.92).
CONCLUSION CONCLUSIONS
The results indicate a connection between the sarcopenia components and cognitive impairments. Limitations in the sarcopenia measures, especially slow walking speed, were related to poorer cognitive outcomes. More investigationsare required to further verify the causal relationship between sarcopenia and cognitive outcomes.

Identifiants

DOI: 10.3233/JAD-221186 PMID: 37899056 PMC: PMC10657697
pubmed: 37899056
pii: JAD221186
doi: 10.3233/JAD-221186
pmc: PMC10657697
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

777-788

Références

Exerc Sport Sci Rev. 2010 Jul;38(3):105-13
pubmed: 20577058
Lancet. 2006 Apr 15;367(9518):1262-70
pubmed: 16631882
Int J Environ Res Public Health. 2021 Jul 09;18(14):
pubmed: 34299801
Sci Rep. 2020 Jun 25;10(1):10367
pubmed: 32587294
J Alzheimers Dis. 2016 Nov 1;55(1):1-18
pubmed: 27636853
Arch Neurol. 2010 Apr;67(4):428-33
pubmed: 20385908
J Gerontol A Biol Sci Med Sci. 2019 May 16;74(6):943-948
pubmed: 29917045
Int Psychogeriatr. 2020 May;32(5):601-610
pubmed: 31762429
J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2
pubmed: 32033882
Clin Nutr. 2015 Jun;34(3):335-40
pubmed: 25799486
J Alzheimers Dis. 2020;73(3):1157-1166
pubmed: 31884487
Front Neurol. 2018 Aug 28;9:710
pubmed: 30210435
J Nutr Health Aging. 2009 Dec;13(10):881-9
pubmed: 19924348
Front Aging Neurosci. 2021 Feb 04;13:625551
pubmed: 33613270
Int J Mol Sci. 2020 Nov 22;21(22):
pubmed: 33266508
Curr Alzheimer Res. 2016;13(6):718-26
pubmed: 26863996
Neurology. 2022 Nov 8;99(19):e2102-e2113
pubmed: 36130840
J Nutr Health Aging. 2019;23(6):525-531
pubmed: 31233073
Arch Gerontol Geriatr. 2016 Jul-Aug;65:63-9
pubmed: 26991478
J Gerontol A Biol Sci Med Sci. 2013 Apr;68(4):412-8
pubmed: 22987797
BMJ. 2015 Jun 16;350:h3029
pubmed: 26079686
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Int J Environ Res Public Health. 2019 Apr 27;16(9):
pubmed: 31035553
JAMA Netw Open. 2022 Jul 1;5(7):e2219926
pubmed: 35796211
Age Ageing. 1997 Jan;26(1):15-9
pubmed: 9143432
Lancet. 2019 Jun 29;393(10191):2636-2646
pubmed: 31171417
J Gerontol A Biol Sci Med Sci. 2005 Oct;60(10):1304-9
pubmed: 16282564
Nat Rev Neurol. 2017 Aug;13(8):457-476
pubmed: 28708131
J Gerontol A Biol Sci Med Sci. 2017 Jun 01;72(6):846-854
pubmed: 28177065
Age Ageing. 2019 Jan 1;48(1):48-56
pubmed: 30052707
Transl Psychiatry. 2020 Apr 21;10(1):112
pubmed: 32317627
Int J Environ Res Public Health. 2023 Jan 07;20(2):
pubmed: 36673844
Clin Nutr. 2020 Sep;39(9):2695-2701
pubmed: 31917049
Eur J Clin Nutr. 2013 Jan;67 Suppl 1:S14-21
pubmed: 23299866
Am J Prev Med. 2011 Aug;41(2):207-15
pubmed: 21767729
Alzheimers Dement. 2017 Mar;13(3):296-311
pubmed: 27825022
Korean J Fam Med. 2017 May;38(3):111-115
pubmed: 28572885
Arch Intern Med. 2012 Apr 23;172(8):666-8
pubmed: 22529236
Nat Rev Neurol. 2018 Nov;14(11):653-666
pubmed: 30291317
J Musculoskelet Neuronal Interact. 2014 Dec;14(4):425-31
pubmed: 25524968
Lancet. 2015 Feb 7;385(9967):549-62
pubmed: 25468153
Clin Geriatr Med. 2017 Feb;33(1):17-26
pubmed: 27886695
J Nutr Health Aging. 2020;24(1):83-90
pubmed: 31886813
Exp Gerontol. 2020 Mar;131:110801
pubmed: 31887347

Auteurs

Liss Elin Larsson (LE)

Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.
The Swedish School of Sport and Health Science, GIH, Stockholm, Sweden.

Rui Wang (R)

The Swedish School of Sport and Health Science, GIH, Stockholm, Sweden.
Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Tommy Cederholm (T)

Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.
Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, Sweden.

Fleur Wiggenraad (F)

Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.
Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.

Marie Rydén (M)

Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.

Göran Hagman (G)

Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.
Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.

Mai-Lis Hellénius (ML)

Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Miia Kivipelto (M)

Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.
Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.
The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, United Kingdom.

Charlotta Thunborg (C)

Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.
Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Mälardalen University Department of Health and Welfare, Sweden.
Department of Caring Sciences, Faculty of Health and Occupational Studies, University of Gävle, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Association of Sarcopenia and Its Defining...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Association of Sarcopenia and Its Defining...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Manifestations neuromusculaires › Amyotrophie › Sarcopénie › Association of Sarcopenia and Its Defining...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Force musculaire › Association of Sarcopenia and Its Defining...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Association of Sarcopenia and Its Defining...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Force musculaire › Force de la main › Association of Sarcopenia and Its Defining...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Mouvement › Locomotion › Démarche › Vitesse de marche › Association of Sarcopenia and Its Defining...